NCT01530815

Brief Summary

The investigators are testing to see if infusion of bupivicaine between the mesh and abdominal wall can reduce postoperative pain and decrease use of narcotics in the postoperative setting.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable postoperative-pain

Timeline
Completed

Started Aug 2011

Typical duration for not_applicable postoperative-pain

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

February 8, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 10, 2012

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2013

Completed
Last Updated

February 10, 2012

Status Verified

February 1, 2012

Enrollment Period

1.4 years

First QC Date

February 8, 2012

Last Update Submit

February 9, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain

    We will measure pain based on pain journal and usage of postoperative pain medication

    24 hours

Study Arms (1)

Bupivicaine Infusion

EXPERIMENTAL

We will infuse bupivicaine between the abdominal wall and mesh to try and reduce postoperative pain

Drug: Bupivicaine Infusion

Interventions

Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall

Also known as: Marcaine
Bupivicaine Infusion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient must be scheduled for a laparoscopic ventral hernia repair at SBCH. If any additional procedure is performed, the subject will be excluded from the study
  • Age 18 or older
  • Patient must agree to complete pain journal postoperatively
  • Informed consent signed and dated by patient. Consenting through a legally authorized guardian will not be accepted due to the necessity of completing a subjective pain journal

You may not qualify if:

  • Any surgical procedure occurring besides the study procedure
  • Any allergy or sensitivity to bupivicaine or its derivatives
  • Less than 18 years of age
  • Patient unable to self report in pain journal due to cognitive disabilities
  • Discharged less than 4 hours post-surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Santa Barbara Cottage Hospital

Santa Barbara, California, 93105, United States

RECRUITING

Related Publications (1)

  • Gough AE, Chang S, Reddy S, Ferrigno L, Zerey M, Grotts J, Yim S, Thoman DS. Periprosthetic Anesthetic for Postoperative Pain After Laparoscopic Ventral Hernia Repair: A Randomized Clinical Trial. JAMA Surg. 2015 Sep;150(9):835-40. doi: 10.1001/jamasurg.2015.1530.

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Bupivacaine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Steve S Chang, MD

    Santa Barbara Cottage Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Steve Chang, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDIV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 8, 2012

First Posted

February 10, 2012

Study Start

August 1, 2011

Primary Completion

January 1, 2013

Study Completion

January 1, 2013

Last Updated

February 10, 2012

Record last verified: 2012-02

Locations